65,437 trials
Healthy Participants
Primary: Evaluation of the Bioequivalent Rate of Absorption (Cmax) of Riluzole After Replicate Single Dose Administration of Test and Reference — 315.62; 278.81 ng/mL — p=<0.0001
Depression · Psychological Distress
Primary: Feasibility of DBS Collection as Measured by Number of Participants Who Provide DBS — 89; 29; 98; 24 Participants
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps. — -2.13; -2.06 score on a scale
Mental Health Disorder · Eating Disorders · Pregnancy Related
Primary: Number of Participants With Each Type of Personal Features Associated With Worsening or Relapse of Eating Disorder Symptoms During Pregnancy (Time Point 1) — 5; 3; 3; 4…
Elevated Blood Sugar
Primary: Perceived Autonomy Support — 6.78; 6.85; 6.77 score on a scale
Fluid Loss · Blood Loss
Primary: Impact of Subject Positioning on Percent Change of Heart Rate (HR) After Minor Blood Loss (e.g., 500mL) — 10.7; 14.7 percent change
Atopic Dermatitis
Primary: Part 1 (Phase I) Primary: Maximum Tolerable Dose — 29.2 Grams of IP per application
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants
Psychiatric Diagnosis
Primary: Feasibility of the App — 88 percentage of visits completed
Fatigue · Sleep Disturbance · Circadian Dysregulation
Primary: Study Completion — 7; 5 Participants
Acute Kidney Injury Due to Sepsis
Primary: Maximum Serum Concentration (Cmax) of TIN816 — 40.8 ug/mL
Early Ambulation
Primary: Penetration — 4.3; 2.2 percentage of eligible hospitalizations — p=0.15
Ligament Injury
Primary: Injury — 8; 16 Participants
Type 2 Diabetes
Primary: Describe CGM Data Use by 15 of the Participants During the UNITE/MyDiabetes Study — 15; 15 Participants
Retinitis Pigmentosa
Primary: Change in Humphrey Visual Fields - Total Sensitivity — 1.4; 16.8; -164.8; -66.7 dB